Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland.

Aysegül AksanAlain SchoepferPascal JuilleratStephan VavrickaMiguel BettencourtAntonio Ramirez de ArellanoSimona GavataNeige MorinWilliam J ValentineBarnaby Hunt

Published in: Advances in therapy (2020)

FCM was projected to be the most cost-effective intravenous iron therapy in Switzerland, increasing the number of responders and leading to cost savings for healthcare payers.

Keyphrases

iron deficiency
patients with inflammatory bowel disease
healthcare
climate change
high dose
stem cells
low dose
combination therapy
replacement therapy
health information
cell therapy
health insurance